Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marina A Parry

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Cancer Epidemiology|February 28, 2026
Comparing the national cancer waiting times dataset with other linked electronic health records to measure treatment timeliness: A national cohort study of kidney cancer in EnglandRaghav Varma, Emily Mayne, Marina A Parry, et al.
European Urology|December 30, 2020
A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological ResearchJoseph M Norris, Benjamin S Simpson, Rhys Ball, et al.
BMJ Open|January 30, 2020
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysisJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
BJU International|October 11, 2019
Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stockJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
European Urology Open Science|October 1, 2020
Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic AnalysisJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
European Urology Oncology|April 2, 2019
Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate CancerMarina A Parry, Shambhavi Srivastava, Adnan Ali, et al.
The Journal of Clinical Investigation|March 31, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancerLarissa Mendes, Peter F Dutey-Magni, Emily Grist, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Cancer Research|January 23, 2016
Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk LocusNicola J Camp, Wei-Yu Lin, Alex Bigelow, et al.
The Lancet. Digital Health|June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocolCharles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancer Epidemiology|February 28, 2026
Comparing the national cancer waiting times dataset with other linked electronic health records to measure treatment timeliness: A national cohort study of kidney cancer in EnglandRaghav Varma, Emily Mayne, Marina A Parry, et al.
European Urology|December 30, 2020
A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological ResearchJoseph M Norris, Benjamin S Simpson, Rhys Ball, et al.
BMJ Open|January 30, 2020
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysisJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
BJU International|October 11, 2019
Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stockJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
European Urology Open Science|October 1, 2020
Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic AnalysisJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
European Urology Oncology|April 2, 2019
Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate CancerMarina A Parry, Shambhavi Srivastava, Adnan Ali, et al.
The Journal of Clinical Investigation|March 31, 2026
Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancerLarissa Mendes, Peter F Dutey-Magni, Emily Grist, et al.
JCO Precision Oncology|January 20, 2022
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialClare Gilson, Fiona Ingleby, Duncan C Gilbert, et al.
Cancer Research|January 23, 2016
Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk LocusNicola J Camp, Wei-Yu Lin, Alex Bigelow, et al.
The Lancet. Digital Health|June 4, 2025
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocolCharles T A Parker, Larissa Mendes, Vinnie Y T Liu, et al.
Pageof 2